ArticleBreast cancer research : BCR2020

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.

Neil A O'Brien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.